{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-046728","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.754742+00:00","generated_at":"2026-05-30T00:15:53.791660+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galectin Therapeutics reports Q3 net loss of $11.2M; NAVIGATE trial top-line results expected Dec 2024","bullets":["Net loss $11.2M ($0.18/share) vs $14.0M ($0.24) in Q3 2023; R&D expense $7.6M, G&A $1.5M.","Cash $27.1M at Sept 30, 2024; $6M credit line from chairman; runway through May 2025.","NAVIGATE trial of belapectin in MASH cirrhosis top-line efficacy/safety results expected December 2024.","Three belapectin abstracts accepted for poster presentation at AASLD 2024 annual meeting.","Annual stockholder meeting set for January 23, 2025 due to NAVIGATE trial timing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-046728","json":"https://secwatch.observer/filing/0001140361-24-046728.json","markdown":"https://secwatch.observer/filing/0001140361-24-046728.md","text":"https://secwatch.observer/filing/0001140361-24-046728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/0001140361-24-046728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/ef20038321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:15:53.791660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}